Efficacy News and Research

RSS
Research programs embody the promise of anti-aging medicine.

Research programs embody the promise of anti-aging medicine.

Combination therapy improves tumor response in HER2-positive breast cancer patients

Combination therapy improves tumor response in HER2-positive breast cancer patients

Novelos NOV-002 demonstrates positive results in Phase 2 neoadjuvant breast cancer trial

Novelos NOV-002 demonstrates positive results in Phase 2 neoadjuvant breast cancer trial

Argos' AGS-004 shows feasibility in in vitro models to generate DC from viremic patients

Argos' AGS-004 shows feasibility in in vitro models to generate DC from viremic patients

Researchers present Phase III study of neoadjuvant therapy with trastuzumab and lapatinib for early breast cancer

Researchers present Phase III study of neoadjuvant therapy with trastuzumab and lapatinib for early breast cancer

Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension

Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension

Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results

Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results

Spherix Phase 2 diabetes clinical trial determines minimum D-tagatose dose capable of reducing HbA1c

Spherix Phase 2 diabetes clinical trial determines minimum D-tagatose dose capable of reducing HbA1c

Prometheus, UCLA collaborate to identify biological markers of mucosal healing in IBD

Prometheus, UCLA collaborate to identify biological markers of mucosal healing in IBD

Biovex announces OncoVEXGM-CSF Phase 3 study for head and neck cancer

Biovex announces OncoVEXGM-CSF Phase 3 study for head and neck cancer

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

Scientists to develop ultra-rapid sexually transmitted infection detection system for clinics

Scientists to develop ultra-rapid sexually transmitted infection detection system for clinics

BDSI initiates dosing in BEMA Buprenorphine Phase 3 clinical program for chronic pain

BDSI initiates dosing in BEMA Buprenorphine Phase 3 clinical program for chronic pain

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

New software predicts key information about nasal insulin treatment regimens in type 1 diabetes

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

Euthymics announces EB-1010 Phase II data for major depressive disorder at ACNP meeting

Euthymics announces EB-1010 Phase II data for major depressive disorder at ACNP meeting

Euthymics's EB-1010 effective in treatment of major depressive disorder: Study

Euthymics's EB-1010 effective in treatment of major depressive disorder: Study

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.